SeaStar Medical Holding Corporation (ICU) Stock Analysis & Winston Score
SeaStar Medical is a small medical device company focused on treating a dangerous condition called systemic inflammation, which happens when the body's immune system goes into overdrive and starts damaging its own organs. Its main product is the Selective Cytopheretic Device, or SCD, which filters a patient's blood to remove harmful immune cells before returning it to the body. The device is used in hospital intensive care units, targeting critically ill patients whose kidneys are failing due to this immune overreaction. The company earns revenue by selling its SCD device and related disposable components to hospitals, primarily in the United States. SeaStar Medical is very small, with a market cap near zero and deep operating losses, meaning it spends far more than it earns right now. The company received FDA Breakthrough Device designation, which helped it gain early market access, but its biggest challenge is scaling hospital adoption and raising enough capital to survive while it builds a commercial business.
Winston Score: 24/100 — Weak
Weak fundamentals across most pillars.
- Quality: Mixed (10/30)
- Growth: Mixed (6/20)
- Cash Flow: Weak (0/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Weak (2/15)
